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INTRODUCTION
Malignant upper gastrointestinal (GI) obstruction is a late 
complication of advanced esophageal, gastric, duodenal, 
or periampullary malignancies (including carcinoma of the 
head of the pancreas, distal bile duct, or ampulla of Vater). 
It leads to malnutrition and a decrease in the quality of 
life. Patients are at risk of aspiration and pneumonia (1). 
Obstruction greatly diminishes the quality of life in these 
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patients who have a limited life expectancy (2). self-
expandable metal stent (SEMS) are being increasingly used 
as a safe and effective alternative to surgery or repetitive 
endoscopic procedure to improve the quality of life for 
patients with upper GI diseases and disorder. Patients 
who are not surgical candidates can benefit from upper 
GI stenting to alleviate obstruction, provided there is no 
perforation or peritonitis. Recent reports (3-9) describe 
SEMS placement as a desirable alternative to bypass surgery, 
which is associated with significant risks of morbidity 
and mortality. Accordingly, we reviewed our experience 
with SEMS placed for the palliation of malignant upper GI 
obstruction with the aim of assessing the feasibility, safety, 
and efficacy of this treatment.
MATERIALS AND METHODS
Patients
Patients who underwent SEMS placement from June 1998 
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in Table 1. Mean patient age was 69 years (range, 43-93  
years) and 51 patients were male. The obstruction of the 
upper GI tract was caused by esophageal cancer in 27 
(32.9%) patients, gastric cancer in 38 (46.3%), pancreatic 
cancer in 10 (12.2%), bile duct cancer in 4 (4.9%), 
gallbladder cancer in 1 (1.2%), and other malignancies 
in 2 (2.4%). The site of obstruction was the esophagus 
in 28 patients (34.1%), the esophago-gastro junction 
(EGJ) in 10 (12.2%), the gastric body in 1 (1.2%), the 
pylorus in 13 (15.9%), the anastomosis side in 12 (14.6%) 
(eophagojejunostomy in 1, gastroduodenostomy in 3, 
gastrojejunostomy in 8), and the duodenum in 18 (22.0%) 
patients. Seven of the 27 patients with esophageal cancer 
had a bronchoesophageal fistula. Six of these 7 patients 
received chemoradiation therapy before stent placement. 
Fifty of the 82 patients could not tolerate any kind of food 
before treatment.
Materials and Methods
Patients underwent endoscopy with fluoroscopic guidance 
to delineate the length of obstruction. Placement of clips 
was performed in selected patients at the discretion of 
the endoscopist to mark the proximal and distal end of 
a stricture. SEMS placement was performed over a guide 
wire under endoscopic and/or fluoroscopic guidance. The 
stent used in all patients for the June 1998-February 2010 
period was the Ultraflex™ Esophageal Stent System (Boston 
Scientific Co., Natick, MA, USA). We extended the delivery 
system when we placed the stent for gastroduodenal 
obstruction. Also, we introduced the WallFlex™ Duodenal 
Stent (Boston Scientific Co., Natick, MA, USA) from February 
2010 for gastric outlet and duodenal obstruction. Ultraflex™ 
Esophageal Stent System is available in diameters of 17 
and 22 mm (covered type), 18 mm (noncovered type) and 
lengths of 10, 12, and 15 cm (covered type), and 7, 10 
and 15 cm (noncovered type). WallFlex™ Duodenal Stent 
is available in a diameter of 22 mm, and lengths of 60, 90 
and 120 mm. The attending endoscopist determined the 
diameter and length of SEMS according to the disease state 
of the patient. Basically, covered SEMS was used for the 
obstruction of esophagus and EGJ. In contrast, noncovered 
SEMS was used for the gastric outlet obstruction (GOO). 
Technical success was defined as correct placement of the 
stent across the stricture, with patency. 
Perforation, stent migration, and hemorrhage were 
considered as early complications (< 72 h).  Late 
complications (≥ 72 h) were migration, perforation, and 
to May 2011 for palliation of malignant upper GI obstruction 
were identified by reviewing hospital records, clinical notes 
and endoscopy procedure reports. All patients were deemed 
to be poor candidates for primary surgical intervention 
based on advanced disease or comorbidities. Data were 
obtained from hospital records, clinical notes, endoscopy 
procedure reports, and follow up clinical visits after 
stenting. Data collected included patient demographics, 
indication for stenting including the type of malignancy 
and the site of the malignant obstruction, the gastric outlet 
obstruction scoring system (GOOSS) score before and after 
stenting, the type of enteral stent, the length of hospital 
stay, complications, and survival.
A total of 82 patients underwent SEMS placement with 
malignant upper GI obstruction between June 1998 and May 
2011. The characteristics of the 82 patients are summarized 
Table 1. Patient Data 
Characteristic n = 82 (%)
Age (years)
< 60 18 (22.0)
60-69 23 (28.0)
≥ 70 41 (50.0)
Mean (range) 69 (43-93)
Gender
Male 51 (62.2)
Female 31 (37.8)
Malignancy
Esophageal cancer 27 (32.9)
Gastric cancer 38 (46.3)
Pancreatic cancer 10 (12.2)
Bile duct cancer 4 (4.9)
Gallbladder cancer 1 (1.2)
Other 2 (2.4)
Location of obstruction
Esophagus 28 (34.1)
Esophago-gastro junction 10 (12.2)
Gastric body 1 (1.2)
Pylorous 13 (15.9)
Anastomosis site
Esophagojejunostomy 1 (1.2)
Gastorduodenostomy 3 (3.7)
Gastorojejunostomy 8 (9.8)
Duodenaum
1st part 3 (3.7)
2nd part 14 (17.0)
3rd part 1 (1.2)Korean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S100
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tumor ingrowth. Patients were observed for 72 hours 
after stenting monitor for early complications. A clear 
liquid diet was allowed from the morning following the 
stenting, and the diet was advanced as tolerated. Clinical 
results and number of days from the time of stenting and 
discharge from the hospital were noted. We also recorded 
when a second stent was placed. If the patients could be 
discharged from the hospital, they were seen in the out-
patient clinic of our hospital every 1-4 weeks. 
Statistical Analysis
Data are shown as a number (%) for categorical variables 
or as mean (range) for continuous variables. The degree of 
dysphagia was assessed before and after stent placement by 
using an adaptation of GOOSS produced by Adler and Baron 
(10), with swallowing ability divided into 4 categories: 0, 
no oral intake; 1, liquids only; 2, soft solid; 3, low-residue 
or full diet (Table 2). Pre- and post-stenting GOOSS score 
were analyzed by using the Chi-square test. Cumulative 
patient survival was estimated by using the Kaplan-Meier 
method. The significance of difference in survival time 
after stent placement was determined by Log-rank test. A 
p value of less than 0.05 was considered to be statistically 
significant. Analysis was performed using SSPS software 
version 11.0J (SPSS Inc., Chicago, IL, USA).
RESULTS
Stent Placement
The initial stent placement was successful in 77 of 82 
patients (93.9%). Five patients had  technical failure at the 
first treatment; in 3 patients the delivery device did not 
pass the malignant stricture, in 2 the SEMS was placed at an 
inadequate position. These two patients in whom SEMS were 
placed at the inadequate position underwent a second stent 
placement successfully. Therefore, technical success was 
achieved finally in 79 patients (96.3%). Of the 79 patients 
in which a SEMS was placed, 6 (7.6%) were performed with 
the TTS delivery technique and 73 (92.4%) with the non-
TTS technique. The detail of the type of SEMS and presence 
or absence of cover according to the site of obstruction are 
shown in Tables 3, 4.
Clinical Observations
All patients were followed until May 2011 or death. Thirty-
five patients were able to be discharged from the hospital. 
Of the 79 patients with successful SEMS placement, 77 were 
able to tolerate oral intake without obstructive symptoms, 
giving a clinical success rate of 97.5%. Two patients who 
could not tolerate an oral intake after successful stent 
placement appeared to have peritoneal dissemination. 
At baseline 50 patients (61%) were incapable of any oral 
intake (GOOSS score = 0) , and 23 (28%) could tolerate 
liquids only (GOOSS score = 1). After SEMS placement, 57 
patients (69.5%) had been able to resume solid food (GOOSS 
score = 2-3). GOOSS score showed a statistically significant 
improvement before (mean, 0.56) and after (mean, 1.92) 
(p < 0.001) stent placement (Table 5). Thirty-five of 82 
patients were able to discharge after SEMS placement, 
Table 2. GOOSS, adapted from Adler et al 
Level of Oral Intake GOOSS Score
No oral intake 0
Liquids only 1
Soft solids 2
Low-residue or full diet 3
Note.— GOOSS = gastric outlet obstruction scoring system
Table 3. Type of SEMS 
Type of SEMS n = 79 (%)
WallFlex™ Duodenal Stent 6 (7.6)
Ultraflex™ Esophageal Stent System (noncovered)36 (45.6)
Ultraflex™ Esophageal Stent System (covered) 37 (46.8)
Note.— SEMS = self-expandable metal stent
Table 4. Presence or Absence of Cover Based on Site of 
Obstruction
Type of SEMS
n = 79 (%)
Esophagus/EGJ GOO
Noncovered type 9 (11.4) 33 (41.8)
Covered type 29 (35.4) 8 (10.1)
Note.— EGJ = esophago-gastro junction, GOO = gastric outlet 
obstruction, SEMS = self-expandable metal stent
Table 5. GOOSS Score before And after Stenting
n = 82 (%)
P
Before After
GOOSS score
0 50 (61.0) 7 (8.5)
1 23 (28.0) 18 (22.0)
2 6 (7.3) 37 (45.1)
3 3 (3.7) 20 (24.4)
Efficacy results (GOOSS score) 
Mean GOOSS score 0.56 1.92 < 0.001
Note.— GOOSS = gastric outlet obstruction scoring systemKorean J Radiol 13(Suppl 1), Jan/Feb 2012 kjronline.org S101
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with a median time from SEMS placement to discharge of 
18 days (range, 1-76). The median length of the hospital 
stay of patients who were not able to discharge was 32 
days (range, 7-100). The mean length of hospital stay of 
the patient who was possible for discharge and the patient 
who was impossible were 23 days and 36.9 days (p < 0.01), 
respectively.
Complications
There was no early complication (< 72 h). The late 
complications (≥ 72 h) arose in 12 patients (14.6%). 
Stent migration occurred in 1 patient (1.2%) on day 29, 
perforation in 1 (1.2%) with esophageal cancer after 
chemoradiation therapy on day 105, and obstruction 
of stent due to tumor ingrowth in 10 (12.2%). Eight of 
10 patients with tumor ingrowth required second SEMS 
placement, and one of the other two was treated by Argon 
Plasma Coagulation. Obstruction of the stent due to tumor 
ingrowth occurred only in a noncovered stent (Fig. 1).
Survival and Stent Patency
Eighty-one of 82 patients died during the follow-up 
period. The median survival time after stenting was 52 
days (6-445) (Fig. 2). The median survival time of patients 
with noncovered SEMS placement and covered were 54 
and 47 days, respectively. Also, there was no statistically 
significant difference between these two groups (Fig. 3). 
The obstruction of the SEMS due to tumor ingrowth was 
observed in 10 patients with a median time from SEMS 
placement to obstruction of 129 days (range, 35-216). 
Fig. 1. Complications according to location of obstruction and type of SEMS. EGJ = esophago-gastro junction
Esophagus/EGJ 38 (46.3%)
Covered 29 (35.4%)
Noncovered 9 (11.0%)
Migration 1 (1.2%)
Perfotration 1 (1.2%)
Ingrowth 2 (2.4%)
Gastroduodenum 44 (53.7%)
Covered 8 (9.8%)
Noncovered 33 (40.2%)
Failure 3 (3.7%)
Ingrowth 8 (9.8%)
Fig. 2. Survival of all patients after SEMS placement. SEMS = self-
expandable metal stent
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Fig. 3. Survival depending on type of stent. SEMS = self-
expandable metal stent
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DISCUSSION
Malignant obstructions of the upper GI tract are frequent 
complications of advanced primary or metastatic tumors, 
generally as a terminal event in the malignancies, with 
poor life expectancy. In our series the most common 
location of malignant obstruction was the esophagus 
(34.1%). Esophageal cancer is the sixth leading cause of 
death from cancer worldwide (11, 12). More than 50% 
of patients with esophageal cancer are inoperable at the 
time of diagnosis, either because of advanced disease 
or due to the presence of comorbid conditions. SEMS 
placement has been widely accepted to be an effective 
option for palliation of the symptoms caused by malignant 
esophageal strictures. Several studies have reported 
excellent results in relief of dysphagia using SEMS (13-15). 
SEMS insertion is an effective way of relieving dysphagia 
in patients with inoperable carcinoma esophagus but 
it is not without complications. Perforation is one of 
most serious complication in patients with malignant 
dysphagia, and mortality rate is high. We also experienced 
perforation in one patient with esophageal obstruction after 
chemoradiation therapy and it was fatal. 
The most common malignancy in our series was gastric 
cancer, and the number of patients with GOO was 43 
(52.4%). Malignant GOO remains a challenging clinical 
condition. The main goal of the treatment is amelioration 
of the obstructive symptoms and the resumption of oral 
intake. Presently, standard treatment is palliative surgery, 
eg, gastrojejunostomy. Given the apparent preterminal 
nature of this event and short life expectancy, less invasive 
treatment, such as enteral stent placement, would appear 
favorable. In fact, endoscopic enteral stent placement has 
been stated to be a feasible, safe, effective alternative. Two 
recent meta-analyses comparing enteral stent placement 
with gastrojejunostomy have also confirmed the high 
technical and clinical success rates of stent placement and 
indicated favorable short-term outcomes with stenting 
(16, 17). In 2002, Adler and Baron (10) introduced the 
GOOSS scale for grading the clinical degree of gastric outlet 
obstruction both before and after treatment, and that 
scale is being increasingly adopted. A number of studies 
have demonstrated improved GOOSS results after stent 
placement (18-24). In our review, the GOOSS score showed 
a statistically significant improvement before (mean, 
0.56) and after (mean, 1.92) (p < 0.001) SEMS placement. 
Although tumor ingrowth is the main cause of recurrent 
obstruction with noncovered SEMS, stent migration occurs 
more often with covered stents than with noncovered ones 
because the smooth surface of the covering reduces friction 
between the stent and the bowel wall (20, 25). We used 
noncovered stents for the palliative endoscopic treatment 
of malignant GOO to prevent migration. In our review, 
the median time from SEMS placement to obstruction due 
to tumor ingrowth (129 days) was longer than median 
survival time (52 days). Therefore, noncovered SEMS 
should be placed in patients with a short life expectancy 
to prevent migration. Here we reviewed SEMS placement 
in 82 patients with upper GI tract obstruction. Results 
were comparable with those of previous studies in terms of 
technical success (96.3%), clinical success (97.5%), rate 
of sever complication (perforation) (1.2%), and rate of 
stent obstruction due to tumor ingrowth (12.2%). However 
median survival time was shorter than that of previous 
studies (10, 20, 21). As a reason for that, 50% of all 
patients were aged above 70 years old in our review. 
In summary, our review of SEMS placement for palliation 
of malignant upper GI obstruction showed comparable 
outcomes and frequency of complications, such as 
migration, obstruction, and perforation to previous studies. 
Our data also confirm that SEMS placement for malignant 
upper GI obstruction is an effective and safe procedure, 
with good clinical outcome. 
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